A cost-effectiveness analysis of three treatments for age-related macular degeneration

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Methods: The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare reimbursable costs for each treatment and associated medical procedures. A multistate transition model with 3-month cycles was created to compare incremental medical costs associated with pegaptanib or ranibizumab versus PDT for patients with starting vision of 20/40, 20/80, and 20/200 Snellen equivalent. Results: Two-year medical treatment costs ranged from $3,100 to $54,100 depending on treatment and lesion type. Photodynamic therapy was less costly and more effective than pegaptanib for predominantly classic and minimally classic lesions. Ranibizumab was not only more effective but also more costly than PDT for all lesion types. Conclusion: Compared with PDT, pegaptanib is inferior in both cost and effectiveness, whereas ranibizumab has a greater effectiveness. Because ranibizumab does not meet 1 of the common thresholds for being considered cost effective (

Original languageEnglish (US)
Pages (from-to)212-221
Number of pages10
JournalRetina
Volume30
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Photochemotherapy
Macular Degeneration
Cost-Benefit Analysis
Health Care Costs
Therapeutics
Costs and Cost Analysis
Choroidal Neovascularization
Medicare
Ranibizumab
Injections
pegaptanib

Keywords

  • Age-related macular degeneration
  • Cost effectiveness
  • Pegaptanib
  • Photodynamic therapy
  • Ranabizumab
  • Treatment

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A cost-effectiveness analysis of three treatments for age-related macular degeneration. / Gower, Emily W.; Cassard, Sandra; Bass, Eric B; Schein, Oliver D; Bressler, Neil M.

In: Retina, Vol. 30, No. 2, 02.2010, p. 212-221.

Research output: Contribution to journalArticle

@article{edd0a98b207049a49987eaac79d145e3,
title = "A cost-effectiveness analysis of three treatments for age-related macular degeneration",
abstract = "Purpose: The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Methods: The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare reimbursable costs for each treatment and associated medical procedures. A multistate transition model with 3-month cycles was created to compare incremental medical costs associated with pegaptanib or ranibizumab versus PDT for patients with starting vision of 20/40, 20/80, and 20/200 Snellen equivalent. Results: Two-year medical treatment costs ranged from $3,100 to $54,100 depending on treatment and lesion type. Photodynamic therapy was less costly and more effective than pegaptanib for predominantly classic and minimally classic lesions. Ranibizumab was not only more effective but also more costly than PDT for all lesion types. Conclusion: Compared with PDT, pegaptanib is inferior in both cost and effectiveness, whereas ranibizumab has a greater effectiveness. Because ranibizumab does not meet 1 of the common thresholds for being considered cost effective (",
keywords = "Age-related macular degeneration, Cost effectiveness, Pegaptanib, Photodynamic therapy, Ranabizumab, Treatment",
author = "Gower, {Emily W.} and Sandra Cassard and Bass, {Eric B} and Schein, {Oliver D} and Bressler, {Neil M}",
year = "2010",
month = "2",
doi = "10.1097/IAE.0b013e3181babd8e",
language = "English (US)",
volume = "30",
pages = "212--221",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A cost-effectiveness analysis of three treatments for age-related macular degeneration

AU - Gower, Emily W.

AU - Cassard, Sandra

AU - Bass, Eric B

AU - Schein, Oliver D

AU - Bressler, Neil M

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Methods: The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare reimbursable costs for each treatment and associated medical procedures. A multistate transition model with 3-month cycles was created to compare incremental medical costs associated with pegaptanib or ranibizumab versus PDT for patients with starting vision of 20/40, 20/80, and 20/200 Snellen equivalent. Results: Two-year medical treatment costs ranged from $3,100 to $54,100 depending on treatment and lesion type. Photodynamic therapy was less costly and more effective than pegaptanib for predominantly classic and minimally classic lesions. Ranibizumab was not only more effective but also more costly than PDT for all lesion types. Conclusion: Compared with PDT, pegaptanib is inferior in both cost and effectiveness, whereas ranibizumab has a greater effectiveness. Because ranibizumab does not meet 1 of the common thresholds for being considered cost effective (

AB - Purpose: The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Methods: The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare reimbursable costs for each treatment and associated medical procedures. A multistate transition model with 3-month cycles was created to compare incremental medical costs associated with pegaptanib or ranibizumab versus PDT for patients with starting vision of 20/40, 20/80, and 20/200 Snellen equivalent. Results: Two-year medical treatment costs ranged from $3,100 to $54,100 depending on treatment and lesion type. Photodynamic therapy was less costly and more effective than pegaptanib for predominantly classic and minimally classic lesions. Ranibizumab was not only more effective but also more costly than PDT for all lesion types. Conclusion: Compared with PDT, pegaptanib is inferior in both cost and effectiveness, whereas ranibizumab has a greater effectiveness. Because ranibizumab does not meet 1 of the common thresholds for being considered cost effective (

KW - Age-related macular degeneration

KW - Cost effectiveness

KW - Pegaptanib

KW - Photodynamic therapy

KW - Ranabizumab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=76749111095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749111095&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181babd8e

DO - 10.1097/IAE.0b013e3181babd8e

M3 - Article

C2 - 19940805

AN - SCOPUS:76749111095

VL - 30

SP - 212

EP - 221

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -